Linda Z Penn

List of Publications by Year in Descending Order

104 papers	10,938 citations	48 h-index	104 g-index
118 ext. papers	12,099 ext. citations	8.4 avg, IF	5.92 L-index

#	Paper	IF	Citations
104	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. *European Urology Focus*, **2021**, 7, 537-545	5.1	5
103	Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. *Cell Reports*, **2021**, 35, 109291	10.6	2
102	MYC protein interactors in gene transcription and cancer. *Nature Reviews Cancer*, **2021**, 21, 579-591	31.3	17
101	The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. *Leukemia*, **2021**, 35, 796-808	10.7	6
100	Identifying and Validating MYC:Protein Interactors in Pursuit of Novel Anti-MYC Therapies. *Methods in Molecular Biology*, **2021**, 2318, 45-67	1.4	
99	Rapid 3D phenotypic analysis of neurons and organoids using data-driven cell segmentation-free machine learning. *PLoS Computational Biology*, **2021**, 17, e1008630	5	4
98	Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study. *Canadian Association of Radiologists Journal*, **2021**, 72, 750-758	3.9	
97	Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced -glycosylation Abundance and Branching. *Cancer Research*, **2021**, 81, 2625-2635	10.1	9
96	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. *Cancer Research*, **2021**, 81, 1627-1632	10.1	7
95	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 630-637	6.2	17
94	Image-Based Analysis of Protein Stability. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2020**, 97, 363-377	4.6	0
93	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 622-629	6.2	1
92	Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. *Molecular Oncology*, **2020**, 14, 2533-2545	7.9	6
91	Statins as Anticancer Agents in the Era of Precision Medicine. *Clinical Cancer Research*, **2020**, 26, 5791-5800	12.9	43
90	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. *Molecular Metabolism*, **2019**, 25, 119-130	8.8	28
89	Regulation and Function of the MYC Oncogene **2019**, 1-13		
88	Multiple direct interactions of TBP with the MYC oncoprotein. *Nature Structural and Molecular Biology*, **2019**, 26, 1035-1043	17.6	20

87	Modelling the MYC-driven normal-to-tumour switch in breast cancer. *DMM Disease Models and Mechanisms*, **2019**, 12,	4.1	8
86	Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins. *Cancer Research*, **2018**, 78, 1347-1357	10.1	29
85	MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis. *Molecular Cell*, **2018**, 72, 836-848.e7	17.6	62
84	MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. *Cancer Cell*, **2018**, 34, 579-595.e8	24.3	52
83	MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability. *Nature Communications*, **2018**, 9, 3502	17.4	23
82	Association between depression, glycaemic control and the prevalence of diabetic retinopathy in a diabetic population in Cameroon. *South African Journal of Psychiatry*, **2017**, 23, 983	1	2
81	MYC Deregulation in Primary Human Cancers. *Genes*, **2017**, 8,	4.2	174
80	The interplay between cell signalling and the mevalonate pathway in cancer. *Nature Reviews Cancer* , **2016**, 16, 718-731	31.3	274
79	MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation. *Cell Cycle*, **2016**, 15, 1693-705	4.7	29
78	ChromNet: Learning the human chromatin network from all ENCODE ChIP-seq data. *Genome Biology*, **2016**, 17, 82	18.3	26
77	BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors. *Journal of Proteomics*, **2015**, 118, 95-111	3.9	83
76	Myc and its interactors take shape. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2015**, 1849, 469-83	6	77
75	AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. *Blood*, **2015**, 125, 2120-30	2.2	148
74	Integrating RAS status into prognostic signatures for adenocarcinomas of the lung. *Clinical Cancer Research*, **2015**, 21, 1477-86	12.9	11
73	Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. *Oncotarget*, **2015**, 6, 26909-21	3.3	34
72	Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. *Cancer Research*, **2014**, 74, 4772-82	10.1	41
71	The role of ligand density and size in mediating quantum dot nuclear transport. *Small*, **2014**, 10, 4182-9211		19
70	Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one. *Molecular and Cellular Oncology*, **2014**, 1, e969133	1.2	6

69	BioID data of c-MYC interacting protein partners in cultured cells and xenograft tumors. *Data in Brief*, **2014**, 1, 76-8	1.2	8
68	Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. *Breast Cancer Research and Treatment*, **2014**, 143, 301-12	4.4	43
67	Identification of c-MYC SUMOylation by mass spectrometry. *PLoS ONE*, **2014**, 9, e115337	3.7	16
66	Involvement of Toso in activation of monocytes, macrophages, and granulocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 2593-8	11.5	45
65	MYC phosphorylation at novel regulatory regions suppresses transforming activity. *Cancer Research* , **2013**, 73, 6504-15	10.1	22
64	Identifying gene locus associations with promyelocytic leukemia nuclear bodies using immuno-TRAP. *Journal of Cell Biology*, **2013**, 201, 325-35	7.3	35
63	Identifying Myc interactors. *Methods in Molecular Biology*, **2013**, 1012, 51-64	1.4	2
62	Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding. *Nucleic Acids Research*, **2012**, 40, 6353-66	20.1	75
61	AML Cells Have Altered Mitochondrial Biogenesis and Low Spare Reserve Capacity in Their Respiratory Chain That Renders Them Susceptible to Oxidative Metabolic Stress.. *Blood*, **2012**, 120, 2581-2581	2.2	
60	Role of Pirh2 in mediating the regulation of p53 and c-Myc. *PLoS Genetics*, **2011**, 7, e1002360	6	51
59	AML Cells Have Increased Mitochondrial Mass but Less Reserve in Their Respiratory Chain Complexes Leading to Heightened Sensitivity to Inhibition of Mitochondrial Protein Translation,. *Blood*, **2011**, 118, 3585-3585	2.2	
58	Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. *Cancer Research*, **2010**, 70, 8748-59	10.1	62
57	Dysregulation of the mevalonate pathway promotes transformation. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15051-6	11.5	264
56	Myc: the beauty and the beast. *Genes and Cancer*, **2010**, 1, 532-41	2.9	47
55	Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. *Blood*, **2010**, 115, 4787-97	2.2	71
54	Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. *BMC Cancer*, **2010**, 10, 103	4.8	104
53	Characterization of the apoptotic response of human leukemia cells to organosulfur compounds. *BMC Cancer*, **2010**, 10, 351	4.8	8
52	Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. *International Journal of Cancer*, **2010**, 127, 2936-48	7.5	43

51	Prognostic gene signatures for non-small-cell lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 2824-8	11.5	159
50	Absence of caspase-3 protects pancreatic {beta}-cells from c-Myc-induced apoptosis without leading to tumor formation. *Journal of Biological Chemistry*, **2009**, 284, 10947-56	5.4	17
49	Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. *Laboratory Investigation*, **2009**, 89, 597-606	5.9	205
48	The role of INI1/hSNF5 in gene regulation and cancer. *Biochemistry and Cell Biology*, **2009**, 87, 163-77	3.6	22
47	Reflecting on 25 years with MYC. *Nature Reviews Cancer*, **2008**, 8, 976-90	31.3	1127
46	Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. *Cancer Research*, **2008**, 68, 6688-97	10.1	46
45	Optimization of experimental design parameters for high-throughput chromatin immunoprecipitation studies. *Nucleic Acids Research*, **2008**, 36, e144	20.1	26
44	Comparison of Machine Learning and Pattern Discovery Algorithms for the Prediction of Human Single Nucleotide Polymorphisms **2007**,		2
43	Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 11754-9	11.5	115
42	Three-gene prognostic classifier for early-stage non small-cell lung cancer. *Journal of Clinical Oncology*, **2007**, 25, 5562-9	2.2	195
41	Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. *Molecular Cancer Therapeutics*, **2007**, 6, 1886-97	6.1	54
40	CUL7 is a novel antiapoptotic oncogene. *Cancer Research*, **2007**, 67, 9616-22	10.1	45
39	The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53. *Journal of Biological Chemistry*, **2007**, 282, 11300-7	5.4	40
38	The Oscar-worthy role of Myc in apoptosis. *Seminars in Cancer Biology*, **2006**, 16, 275-87	12.7	108
37	Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. *Clinical Cancer Research*, **2006**, 12, 5632-40	12.9	114
36	The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. *Cancer Research*, **2006**, 66, 5330-7	10.1	384
35	CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. *Nucleic Acids Research*, **2005**, 33, 2952-61	20.1	82
34	A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. *Journal of Molecular Biology*, **2005**, 351, 182-94	6.5	77

33	Cancer therapeutics: targeting the dark side of Myc. *European Journal of Cancer*, **2005**, 41, 2485-501	7.5	132
32	Novel Disulfides with Antitumour Efficacy and Specificity. *Australian Journal of Chemistry*, **2005**, 58, 128	1.2	10
31	Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. *EMBO Journal*, **2005**, 24, 2096-103	13	319
30	Apoptosis and cancer **2005**, 75-95		
29	Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. *Cancer Research*, **2005**, 65, 5607-19	10.1	64
28	Bcl-2 and c-Myc co-operate in the Epstein-Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity. *Leukemia and Lymphoma*, **2005**, 46, 581-92	1.9	3
27	Promoter-binding and repression of PDGFRB by c-Myc are separable activities. *Nucleic Acids Research*, **2004**, 32, 3462-8	20.1	25
26	c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism. *Oncogene*, **2004**, 23, 3481-6	9.2	52
25	Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. *Cancer Research*, **2004**, 64, 6461-8	10.1	186
24	Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. *EMBO Journal*, **2003**, 22, 5459-70	13	150
23	Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. *Current Biology*, **2003**, 13, 882-6	6.3	156
22	Functional analysis of the N-terminal domain of the Myc oncoprotein. *Oncogene*, **2003**, 22, 1998-2010	9.2	69
21	Identifying genes regulated in a Myc-dependent manner. *Journal of Biological Chemistry*, **2002**, 277, 36925-30	5.4	104
20	The myc oncogene: MarvelouslY Complex. *Advances in Cancer Research*, **2002**, 84, 81-154	5.9	347
19	Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. *Neoplasia*, **2002**, 4, 337-46	6.4	69
18	Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. *Blood*, **2001**, 98, 3541-53	2.2	110
17	Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. *Oncogene*, **2001**, 20, 1939-52	9.2	106
16	Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. *Leukemia and Lymphoma*, **2001**, 40, 659-62	1.9	47

15	Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. *Molecular and Cellular Biology*, **2001**, 21, 4725-36	4.8	119
14	Lysophosphatidic acid prevents apoptosis in fibroblasts via Gi-protein-mediated activation of mitogen-activated protein kinase. *Biochemical Journal*, **2000**, 352, 135	3.8	35
13	Myc is an essential negative regulator of platelet-derived growth factor beta receptor expression. *Molecular and Cellular Biology*, **2000**, 20, 6768-78	4.8	49
12	Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. *Leukemia and Lymphoma*, **2000**, 40, 167-78	1.9	71
11	Lysophosphatidic acid prevents apoptosis in fibroblasts via Gi-protein-mediated activation of mitogen-activated protein kinase. *Biochemical Journal*, **2000**, 352, 135-143	3.8	66
10	Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach. *Blood*, **1999**, 93, 1308-1318	2.2	174
9	Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. *Oncogene*, **1999**, 18, 3520-8	9.2	60
8	Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach. *Blood*, **1999**, 93, 1308-1318	2.2	14
7	OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. *Journal of Cell Biology*, **1998**, 141, 1407-14	7.3	164
6	Advances in the Understanding of Apoptosis. *Leukemia and Lymphoma*, **1998**, 30, 59-60	1.9	1
5	The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. *FASEB Journal*, **1998**, 12, 633-651	0.9	307
4	Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. *Journal of Cell Biology*, **1997**, 137, 939-52	7.3	76
3	Myc represses the growth arrest gene gadd45. *Oncogene*, **1997**, 14, 2825-34	9.2	126
2	Induction of apoptosis in fibroblasts by c-myc protein. *Cell*, **1992**, 69, 119-28	56.2	2734
1	Regulation and Function of the MYC Oncogene1-13		